Biogen Canada was established in Mississauga, Ontario in April 1998 and has been conducting business in Canada for more than 20 years. The scope of our operations has continued to expand and has helped to improve the care of individuals affected by multiple sclerosis (MS) and spinal muscular atrophy (SMA).
In Canada, Biogen contributes to the life science sector through its investments in research and development.
There are currently 8 therapy areas where Biogen is doing research in Canada, including: MS, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) or Lou-Gehrig disease, large hemispheric infarction, Parkinson’s Disease, progressive supranuclear palsy, SMA and pain.
Biogen Canada provides important support services to patients in Canada:
- Our Biogen ONE Support Program provides patients with a wide range of services, including patient education, injection training/infusion services, reimbursement and financial assistance support, and monitoring and side effect management.
- More than 60 people (including nurses and reimbursement support specialists) support more than 12,000 patients currently enrolled across Canada.
- SMA 360◦™ is the program supported by Biogen that provides SMA patients and their families with services, including financial assistance.
Biogen Canada provides competitive salaries, comprehensive benefits and flexible working conditions.
Research Hub of Excellence
Biogen Canada recognizes the neuroscience expertise in Canada and is proud to be an industry leader investing heavily into research, development and product innovation in Canada. With a clear dedication to neuroscience, Biogen Canada has built the Canadian Neuroscience Research HUB of Excellence because Canada holds some of the top academic institutions in the world, with renowned researchers who have been part of major clinical breakthroughs in order to advance science and support patients living with neurological conditions.